Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
CJC-1295
Growth Hormone Secretagogues
Molecular Dossier
- Rank Index: 10
- Status: FDA Category 1
- What does this mean?
- Molecular Structure: 30 Amino Acid Peptide (Mod GRF 1-29)
About CJC-1295
A GHRH analog that increases growth hormone levels via natural pulses.
Clinical Focus
GH Stimulation & Recovery
Archival Aliases
Mod GRF 1-29, No DAC
Frequently Asked Questions
What are the strict legal and safety limitations for research-grade peptides?
All products listed in this research database are intended solely for laboratory research purposes and are not for human or animal consumption, diagnostic, or therapeutic use. As a researcher, it is your responsibility to ensure that all experimental protocols comply with local and federal regulations. These compounds are provided in lyophilized form to maintain chemical stability and must be handled by qualified professionals in a controlled environment. Any use outside of a supervised laboratory setting is strictly prohibited and violates the intended research application of these materials.
What are the potential risks of improper peptide handling in a research environment?
Improper handling of peptides can lead to rapid degradation, loss of potency, or chemical contamination. Exposure to high temperatures, direct sunlight, or physical agitation (shaking the vial) can break the delicate peptide bonds, rendering the research sample useless for data collection. Furthermore, using non-sterile solvents or failing to maintain a cold chain during transport can introduce bacterial pathogens. Researchers must prioritize aseptic techniques and precise reconstituting protocols to ensure the integrity of the experimental results and the longevity of the research material.
What is the difference between CJC-1295 with DAC and without DAC?
DAC (Drug Affinity Complex) is a lysine-maleimide modification that binds CJC-1295 to albumin in the bloodstream, extending its half-life from ~30 minutes to 6-8 days. CJC-1295 without DAC (also called Mod GRF 1-29) produces a sharp, short GH pulse mimicking natural release. CJC-1295 with DAC produces a sustained elevation of GH, which some researchers prefer for convenience (once or twice weekly dosing) while others avoid it to preserve natural pulsatility.
How does CJC-1295 work?
CJC-1295 is an analog of growth hormone releasing hormone (GHRH). It binds to GHRH receptors in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone. Unlike synthetic GH, this preserves the body's natural feedback regulation and does not suppress the pituitary over time.
What results can be expected from a CJC-1295 + Ipamorelin protocol?
The combination amplifies both GH pulse amplitude (CJC-1295) and frequency (Ipamorelin) simultaneously. Research subjects typically report improved sleep quality within the first 2-4 weeks, followed by gradual improvements in body composition — lean muscle retention and modest fat loss — over 8-12 weeks. Skin quality improvements and recovery speed are also commonly reported outcomes.
What are the best times to administer CJC-1295?
CJC-1295 without DAC is best administered 30-60 minutes before sleep to amplify the natural nocturnal GH pulse, and optionally again in the morning on an empty stomach. Administration post-workout is also researched to amplify the exercise-induced GH response. Avoid administration immediately after carbohydrate-rich meals, as elevated insulin blunts GH secretion.
Does CJC-1295 cause any side effects?
The most common reported effects include: transient facial flushing and tingling (from histamine release), headache, and water retention at higher doses. Water retention typically subsides as the body adapts. Injection site reactions (redness, swelling) can occur with poor technique. There are no significant cortisol or prolactin elevations, unlike less selective secretagogues.
How does CJC-1295 affect IGF-1 levels?
CJC-1295 elevates both pulsatile GH and downstream IGF-1 produced in the liver. In the original clinical trial (Walker et al., 2006), weekly CJC-1295 with DAC doses increased mean GH levels by 2-10 fold and IGF-1 by 1.5-3 fold over 28 days, with effects persisting up to 6 days post-injection. IGF-1 elevation is responsible for much of the anabolic and recovery signaling.
Is CJC-1295 legal to purchase?
In the United States, CJC-1295 is not FDA-approved and was placed on the FDA Category 2 list in 2024, meaning licensed compounding pharmacies can no longer legally produce it for human use. It exists in a research chemical grey area and can be purchased from research chemical suppliers for non-clinical laboratory use. It is also explicitly prohibited by WADA in sports contexts.
Can CJC-1295 help with anti-aging goals?
The decline in GH and IGF-1 with age (somatopause) is well documented and correlates with changes in body composition, skin quality, bone density, and cognitive function. CJC-1295 addresses this by restoring youthful GH pulsatility without the risks of exogenous GH. Research suggests improvements in lean body mass, skin elasticity, and recovery in older subjects, though long-term human data is limited.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | 30 Amino Acid Peptide (Mod GRF 1-29) |
| Primary Pathway | Growth Hormone Secretagogues |
| Research Phase | FDA Category 1 |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-07